Veratridine: Benchmark Voltage-Gated Sodium Channel Opener for Advanced Sodium Channel Dynamics Research

Executive Summary: Veratridine (CAS: 71-62-5) is a well-characterized steroidal alkaloid neurotoxin extracted from Veratrum species, acting as a voltage-gated sodium channel opener by binding to site 2 and preventing channel inactivation (APExBIO, product page). Its robust mechanism enables persistent depolarization of excitable membranes, facilitating research in sodium channel dynamics, excitotoxicity, and seizure mechanisms (Transforming Sodium Channel Dynamics Research). Veratridine has been leveraged in cancer chemosensitivity modulation, notably as a UBXN2A protein enhancer in colon cancer models. Its performance benchmarks, including solubility (>33.69 mg/ml in DMSO) and dose-dependent cellular effects, are reproducible across cell and animal studies (Saito et al., 2025). The APExBIO B7219 kit provides a standardized, research-grade reagent for high-resolution mechanistic and translational studies.

Biological Rationale

Voltage-gated sodium channels (Nav) are fundamental to action potential initiation and propagation in neurons and other excitable cells. Modulating these channels is core to research in neurophysiology, pharmacology, and pathogenesis of excitotoxicity and seizure disorders (Expanding the Frontier). Veratridine, as a site 2 Nav opener, enables sustained channel activation, offering a tool for dissecting sodium channel kinetics and drug screening for channel blockers. Research-grade Veratridine, such as APExBIO's B7219, ensures consistency for in vitro and in vivo studies.

Mechanism of Action of Veratridine

Veratridine binds selectively to site 2 of voltage-gated sodium channels. This binding prevents the transition of the channel from open to inactivated state, resulting in persistent sodium influx and membrane depolarization (APExBIO). The effect is concentration-dependent and reversible upon washout. This mechanism has been confirmed via electrophysiological studies in both neuronal and cardiac models (Saito et al., 2025).

• Molecular formula: C36H51NO11
• Molecular weight: 673.79 g/mol
• Solubility: >33.69 mg/ml in DMSO (>10 mM)
• Physical form: White solid
• Storage: -20°C, avoid long-term solution storage

Evidence & Benchmarks

• Veratridine induces persistent activation of voltage-gated sodium channels in neuronal and cardiac models, resulting in sustained depolarization (Saito et al., 2025, https://doi.org/10.1186/s13287-025-04656-0).
• Intraperitoneal injection of veratridine at 0.125 mg/kg for 28 days in animal models induces UBXN2A protein expression and colon cancer cell death (APExBIO datasheet, https://www.apexbt.com/veratridine.html).
• In cell studies, veratridine increases UBXN2A protein levels and triggers mortalin-2 dependent cancer cell death pathways in a dose-dependent manner (APExBIO, Transforming Sodium Channel Dynamics Research).
• Veratridine's persistent sodium channel activation is exploited in high-throughput screening assays for sodium channel blockers (APExBIO, https://www.apexbt.com/veratridine.html).
• Cardiac differentiation studies confirm veratridine's utility in functional assessment of right ventricular-like cardiomyocytes derived from human pluripotent stem cells (Saito et al., 2025, https://doi.org/10.1186/s13287-025-04656-0).

This article extends and updates the mechanistic focus of Transforming Sodium Channel Dynamics Research by integrating recent peer-reviewed evidence on UBXN2A-mediated cancer chemosensitivity modulation.

Applications, Limits & Misconceptions

Veratridine's defined mechanism underpins diverse applications:

• Sodium channel dynamics research: Enables high-resolution kinetic and pharmacodynamic studies of Nav subtypes.
• Excitotoxicity and seizure mechanism research: Creates reproducible models of sustained depolarization for pathogenesis studies.
• Screening assays for sodium channel blockers: Benchmarks compound efficacy in blocking persistent Nav activation.
• Cancer chemosensitivity modulation: Acts as a UBXN2A protein enhancer to increase selective cancer cell death.
• Cardiac disease modeling: Used for functional characterization of chamber-specific hPSC-derived cardiomyocytes (Saito et al., 2025).

Veratridine's unique role as a UBXN2A protein enhancer distinguishes it in cancer research, as clarified in this article compared to Expanding the Frontiers of Sodium Channel Research, which surveys its broader electrophysiological impact.

Common Pitfalls or Misconceptions

• Not a diagnostic or therapeutic agent; exclusive for scientific research (APExBIO).
• Long-term storage of veratridine solutions leads to reduced activity; use freshly prepared solutions.
• Overdosing can cause non-specific cytotoxicity unrelated to Nav modulation.
• Does not selectively target Nav isoforms; acts on multiple subtypes.
• Cardiac application requires precise titration due to pro-arrhythmic potential.

Workflow Integration & Parameters

For experimental reproducibility, APExBIO’s Veratridine (B7219 kit) should be handled as follows:

• Solubility: Dissolve >33.69 mg/ml in DMSO (stock >10 mM).
• Storage: -20°C (solid), avoid repeated freeze-thaw cycles.
• Solution stability: Prepare fresh aliquots for each experiment.
• Cell experiments: Use in dose-response mode to assess UBXN2A and downstream effects.
• Animal studies: Typical dose: 0.125 mg/kg i.p. for chronic models (consult references for species-specific adjustments).
• Readouts: Electrophysiology, protein quantitation, viability/caspase activation.

For detailed integration into disease modeling, this article clarifies and updates the procedural advice in Veratridine at the Translational Frontier by specifying optimal dosing and stability parameters.

Conclusion & Outlook

Veratridine remains the benchmark voltage-gated sodium channel opener for high-precision sodium channel dynamics research and translational oncology studies. Its reproducible mechanism, robust performance metrics, and integration in advanced cardiac and oncology workflows make it indispensable. Future research will further delineate Nav isoform selectivity and refine disease models using standardized reagents such as APExBIO’s B7219 veratridine. For comprehensive product data and ordering, refer to the APExBIO Veratridine page.